• Ocugen signed a binding term sheet to license OCU400 for retinitis pigmentosa to Roots Pharmaceutical in the Middle East and North Africa.
• Upfront license fees and near-term development milestones of up to USD 4 million.
• Sales milestones of up to USD 255 million.
• Royalties set at 22% of net sales.
• Ocugen to manufacture and supply commercial OCU400 under a related supply agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130702PRIMZONEFULLFEED9760854) on July 13, 2026, and is solely responsible for the information contained therein.